News

Israeli Pharmaceutical Companies See Decline in Shares

1 Mins read

Shares of Israeli pharmaceutical companies have experienced a drop in premarket trading on Monday in the aftermath of the recent attack by Hamas on Israel.

Teva Pharmaceutical Industries Ltd.

Israeli pharmaceutical giant, Teva Pharmaceutical Industries Ltd. (TEVA), has seen a 4% decrease in its shares.

Taro Pharmaceutical Industries Ltd.

Shares of Taro Pharmaceutical Industries Ltd. (TARO) have also been impacted, with a decrease of 2.6%.

Kamada Ltd.

Biopharmaceutical company, Kamada Ltd. (KMDA), has observed a significant decline of 6.1% in its stock value.

Protalix BioTheraputics Inc.

The stock of Protalix BioTheraputics Inc. (PLX) has experienced a decrease of 5.5%.

Protalix released a statement expressing their condolences and solidarity with the victims of the ongoing attacks in Israel. However, they reassured their employees, partners, and stockholders that their operations remain unaffected by the situation and that there will be no disruption to the supply of their products.

Compugen Ltd.

Drug discovery and development company, Compugen Ltd. (CGEN), has witnessed a 6.6% decrease in shares on Monday.

Gamida Cell Ltd.

Gamida Cell Ltd. (GMDA) has experienced a decline of 7.4% in premarket trades on Monday.

These recent developments highlight the impact of the attack on Israeli society, including its pharmaceutical industry.

Related posts
News

$TRUMP and other meme coins won't be protected by SEC, Commissioner Hester Peirce says

3 Mins read
LAS VEGAS — Now that the SEC is out of the business of regulating meme coins, investors shouldn’t expect any guidance on…
News

Man charged in New York with 3-week kidnapping to try to steal Bitcoin

1 Mins read
NEW YORK (Reuters) -A grand jury has indicted a 37-year-old cryptocurrency investor accused of kidnapping a business partner inManhattan’s upscale Soho neighborhood…
News

Goldman Sachs Expert Predicts Significant Gold Price Surge by 2026

2 Mins read
Investors are advised to consider risk-reward balance and portfolio diversification. Daan Struyven, co-head of global commodities research at Goldman Sachs, has projected…

Leave a Reply

Your email address will not be published. Required fields are marked *